Abstract

A lipid-based nanoparticle (LNP) with high DL ratio and normalized release. The LNP of the present invention comprises an outer lipid monolayer encapsulating a plurality of lipid-active pharmaceutical ingredient (API) complexes, wherein each lipid- API complex comprises a complex of anionic lipid and API wherein the API comprises a positively charged form of an API and wherein the outer lipid monolayer of the LNP comprises neutral lipids. The present invention further comprises a method of preparation of the LNP of the present invention.

IPC Classes  ?

• A61K 9/127 - Liposomes
• A61K 9/51 - Nanocapsules
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/05 - Phenols
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

Provided is a method for diagnosing and monitoring progression of cancer or effectiveness of a therapeutic treatment. The method includes detecting a methylation level of at least one gene in a biological sample containing circulating free DNA. Also provided are primer pairs and probes for diagnosis or prognosis of cancer in a subject in need thereof.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

Provided herein are methods for treating or ameliorating malignant diseases, such as cancers. Also provided herein are methods of increasing the immunity of an immune cell toward malignant cells.

IPC Classes  ?

• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A device is provided to generate a three-dimensional (3D) real image. A display panel is divided into several sub-areas for emitting scenes. Through a projecting lens-array unit, the scenes enter a fusion lens unit to form a real image of light field at a position beyond common barrier. Through an eyepiece unit, the image is emitted to human eye. Thus, the present invention provides a device for near-eye viewing, which reduces existing human-eye vergence accommodation conflict (VAC) in most augmented reality and mixed reality devices. Therein, the display of near-eye light field is a process of light-field reproduction, which merges the scenes and reduces aberration.

IPC Classes  ?

• G02B 27/01 - Head-up displays
• G02B 13/22 - Telecentric objectives or lens systems
• H04N 13/332 - Displays for viewing with the aid of special glasses or head-mounted displays [HMD]

Abstract

Provided is a peptide and method in preventing or treating infections caused by a wide spectrum of pathogens, including bacteria and fungus in hosts such as plants and animals. Methods of preventing or treating plant diseases and infection in animals are also provided.

IPC Classes  ?

• A61P 31/04 - Antibacterial agents
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61K 38/00 - Medicinal preparations containing peptides
• C05G 3/60 - Biocides or preservatives, e.g. disinfectants, pesticides or herbicides; Pest repellants or attractants
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

Embodiments of the present disclosure generally relate to electroluminescent devices, such as organic light-emitting diodes, and displays including electroluminescent devices. In an embodiment is provided an electroluminescent device that includes a pixel defining layer, an organic emitting unit disposed over at least a portion of the pixel defining iayer, and a filler layer disposed over at least a portion of the organic emitting unit, wherein a refractive index of the pixel defining iayer is iower than a refractive index of the filler Iayer, and wherein the refractive index of the pixel defining Iayer is Iower than a refractive index of one or more layers of the organic emitting unit, in another embodiment is provided a display device that includes a substrate, a thin film transistor formed on the substrate, an interconnection electrically coupled to the thin film transistor, and an electroluminescent device electrically coupled to the interconnection.

IPC Classes  ?

• H01L 27/32 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including components using organic materials as the active part, or using a combination of organic materials with other materials as the active part with components specially adapted for light emission, e.g. flat-panel displays using organic light-emitting diodes
• H01L 51/52 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED) - Details of devices
• H05B 33/02 - Electroluminescent light sources - Details

Abstract

Disclosed herein are ACE2-Fc fusion polypeptides that contain at least one binding site for a spike protein of a coronavirus and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such fusion polypeptides.

IPC Classes  ?

• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The field of view (FOV) of a nonlinear optical microscope (NLOM) is expected to be large enough for employing high-speed raster scanning on a mesoscale volumetric biological sample. Concurrently, three-dimensional (3D) visualization of fine sub-micron biological structures requires high enough lateral and axial resolutions, enforcing a high numerical aperture (NA) objective lens to be employed, thereby limiting the FOV of an NLOM. The invention is directed to a laser scanning NLOM, or to a large-angle optical raster scanning system, for deep biological tissue imaging with a large FOV of more than one square millimeter, up to 1.6 ¡ 1.6 mm2, while simultaneously maintaining a sub-femtoliter effective 3D resolution by means of a high-NA and low magnification objective lens and further maintaining a high acquisition speed with synchronized sampling, limited by the repetition rate of a high repetition rate pulsed laser source, thereby exceeding Nyquist Criterion for resolving micro-optical resolution throughout a horizontal FOV of more than one millimeter.

IPC Classes  ?

• G02B 26/10 - Scanning systems
• G02B 26/08 - Optical devices or arrangements for the control of light using movable or deformable optical elements for controlling the direction of light

Abstract

The present invention provides a dental radiograph imaging device and a use thereof; wherein, the dental radiograph imaging device comprises a film holder for placing photosensitive film and a biting plate holding the occlusal surface of a user's teeth. Besides, the position of the film holder on the biting plate can be flexibly adjusted, so it is possible to easily adjust and accurately position the position of the photosensitive film on the tooth to be photographed. Therefore, the dental radiograph imaging device of the present invention can simultaneously reduce discomfort during use and improve the accuracy of capturing images.

IPC Classes  ?

• G03B 42/04 - Holders for X-ray films
• A61B 6/14 - Applications or adaptations for dentistry
• G03B 42/02 - Obtaining records using waves other than optical waves; Visualisation of such records by using optical means using X-rays

Abstract

We utilized a biocompatible hollow polymeric nanoparticle that coencapsulates T cell epitope peptides and olginodeoxynucleotide (ODN) CpG, and designed immunization strategies to evaluate its protectivity against influenza viruses in mice. This nanoparticle-based peptide vaccine adjuvanted with CpG stimulated robust antigen-specific CD4 and CDS T cell immunity, but only caused minimal adverse effects compared with crude mixture of peptides and CpG. We used two peptides derived from the nucleocapsid protein (NP), MHC class I- restricted NP366-374 and MHC class ll-restricted NP311-325. This novel nanoparticle vaccine with two epitope peptides plus CpG induced robust and fully protective T cell immunity against influenza viruses. We demonstrates the utility of this novel hollow nanoparticle with co-encapsulation of only a pair of CD4+ and CD8+ T cell-stimulating influenza viral peptides and CpG in establishing near-sterilizing protective resident T cell immunity against heterosubtypic IAV infections, a critical step towards the development of universal influenza T cell vaccines.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

The present invention is a cardioplegic solution that demonstrates better stability in pH, particulate matter formation and osmolality but at the same time demonstrates superior ability to preserve heart functions than currently available cardioplegic solutions. The cardioplegic solution comprises potassium (K+), magnesium (Mg2+), sodium (Na+), chloride (CI-44 2-), THAM and mannitol dissolved in water.

IPC Classes  ?

• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/255 - Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
• A61K 31/4418 - Non-condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine

Abstract

in vivo in vitro.in vitro.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

3622 (where M = Fe, Ni or Zn), and (ii) the electrochromic device having a first conducting substrate; the film of the cathodically coloring metallo-supramolecular polymer; an electrolyte; the film of the anodically coloring metal hexacyanoferrate (MHCF); and a second conducting substrate being arranged in this order.

IPC Classes  ?

• G02F 1/15 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect
• G02F 1/1516 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising organic material
• G02F 1/1524 - Transition metal compounds
• G02F 1/155 - Electrodes

Abstract

Disclosed herein are disintegrin variants, and methods for suppressing or inhibiting platelet aggregation in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of the present disintegrin variant to alleviate or ameliorate symptoms associated with diseases, disorders, and/or conditions resulted from platelet aggregation. According to preferred embodiments, the present disintegrain variant is applied as a coating on an implantable device, such as a stent or a catheter.

IPC Classes  ?

• C07K 14/46 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates
• C07K 14/745 - Blood coagulation or fibrinolysis factors
• C07K 7/04 - Linear peptides containing only normal peptide links
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

A method and a composite material used for free forming a bone substitute are provided. The composite material comprises a support cloth, and a partially hardened bone paste coated on the support cloth. The bone paste contains a mixture of calcium sulfate and calcium phosphate in a weight ratio of 1 : 1 to 1 :4. The bone substitute can be made by laminating the composite material either on a bone model or not.

IPC Classes  ?

• A61L 24/02 - Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
• A61L 27/02 - Inorganic materials
• A61L 27/10 - Ceramics or glasses
• A61L 27/12 - Phosphorus-containing materials, e.g. apatite
• A61L 27/14 - Macromolecular materials
• A61L 27/40 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 27/50 - Materials characterised by their function or physical properties

Abstract

Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N6-(4-hydroxybenzyl)adenosine and analogous compounds with amino acids or peptides. In one embodiment of the invention, the compound is 5'-glycylcarbonyl-N6-(4-hydroxybenzyl)adenosine (I-a1). In another embodiment of the invention, the compound is 5'-deoxy-5'-(N'- glycylureido)-N6-(4-hydroxybenzyl)adenosine (I-d1). Also disclosed are methods of making and using the same.

IPC Classes  ?

• C07H 19/16 - Purine radicals
• C07H 1/00 - Processes for the preparation of sugar derivatives
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Ironized viral particles such as ironized adeno-associated viral particles, which may carry a photosensitizer such as aKillerRed protein, and uses thereof in light-triggered virotherapy against tumor.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

The invention provides various immunogens comprising a repeat unit of saccharide of Klebsiella pneumoniae CPS, which has a formula selected from the group consisting of Formulae (I) to (VI) as described herein. Also provided are vaccines comprising one or more immunogens selected from Formula (I) to (VI) and methods of eliciting an immune response against a Klebsiella pneumoniae and preventing infection of Klebsiella pneumoniae by using an immunogen of the invention.

IPC Classes  ?

• A61K 39/108 - Escherichia; Klebsiella
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides novel substituted benzimidazole derivatives used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 235/04 - Benzimidazoles; Hydrogenated benzimidazoles
• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Abstract

Disclosed herein are photodynamic insecticide methods and compositions for the control or reduction of insect populations comprising the use of photosensitizer compounds in combination with light.

IPC Classes  ?

• A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
• A01N 55/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing metal atoms

Abstract

The present disclosure provides compounds of Formulas (I), (II), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating proliferative diseases, for example, cancer (e.g., lung cancer), and infectious diseases (e.g., bacterial infections).

IPC Classes  ?

• C07D 307/92 - Naphthofurans; Hydrogenated naphthofurans
• C07D 333/74 - Naphthothiophenes
• C07D 209/56 - Ring systems containing three or more rings
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole

Abstract

The present disclosure provides compounds of Formulas (I') and (I), and pharmaceutically acceptable salts thereof. The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, and uses thereof for treating proliferative diseases.

IPC Classes  ?

• C07D 473/00 - Heterocyclic compounds containing purine ring systems
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Aptamers that bind to and antagonize PDL1 and uses thereof in enhancing immune activity (e.g., promoting T cell proliferation), treating cancer, and/or infectious diseases such as infections caused by enterovirus, HBV, or HCV infection.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links

Abstract

Disclosed is a redox-complementary electrochromic device exhibiting black-to-transmissive switching, wherein the device comprises an electrochromic layer and a redox-active material layer sandwiched between a transparent first electrode and a transparent secondary electrode, the electrochromic layer comprising an electrochromic Co-based metallo-supramolecular polymer represented by the formula (I), and the redox active material being capable of reacting with the electrochromic material to change the electrochromic material from black state into colorless transmissive state. (In the formula (I), X represents a counter anion, R represents a single bond or a spacer comprising a carbon atom and a hydrogen atom, each of R1 to R4 independently represents a hydrogen atom or a substituent group, and n represents an integer of from 2 to 5000, which indicates a degree of polymerization.)

IPC Classes  ?

• G02F 1/15 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect
• C08G 79/00 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon
• C09K 9/02 - Organic tenebrescent materials

Abstract

Silica-based biomolecule carriers, compositions comprising the same and preparation methods and uses thereof for delivering biomolecules into a cell are provided. The silica-based biomolecule carrier comprises a porous core; a first bioactive moiety; a second bioactive moiety functionally associated with the first bioactive moiety; and linkers for respectively conjugating the first bioactive moiety and the second bioactive moiety to the porous core.

IPC Classes  ?

• C08K 5/5415 - Silicon-containing compounds containing oxygen containing at least one Si—O bond
• G01N 33/552 - Glass or silica
• A61K 39/385 - Haptens or antigens, bound to carriers

Abstract

Provided herein are novel pyrazoloquinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, Huntington's disease and nocturnal enuresis;depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 471/14 - Ortho-condensed systems
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Abstract

The present disclosure includes a PINK1-C-terminal domain (PINK1-CTD) polypeptide that binds to ERBB tyrosine kinase domain (ERBB-TKD) and therefore impedes ERBB from dimerization and activation. The PINK1-CTD polypeptide inhibits, prevents and/or treats ERBB-expressing cancers. The disclosure demonstrates the anti-tumor function of the PINK1-CTD, which provides a new direction for ERBB-expressing cancer therapy.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• C07K 14/71 - Receptors; Cell surface antigens; Cell surface determinants for growth regulators
• C07K 19/00 - Hybrid peptides
• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

An in vitro co-culture system comprising cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for identifying agents capable of reducing cancer cell stemness. Also disclosed herein are a paracrine network through which CAFs facilitate production and/or maintenance of cancer stem cells and the use of components of such a paracrine network for prognosis purposes and for identifying cancer patients who are likely to respond to certain treatment.

IPC Classes  ?

• C12N 5/095 - Stem cells; Progenitor cells
• C12N 5/09 - Tumour cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention provides a novel method for treating cancer that comprises administering a compound represented by formula (I) and/or a chemotherapeutic agent to a subject. The present invention further provides a novel kit that comprises a compound represented by formula (I) and a chemotherapeutic agent for treating cancer.

IPC Classes  ?

• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61K 31/405 - Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/4418 - Non-condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/47 - Quinolines; Isoquinolines
• C07D 239/42 - One nitrogen atom
• C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
• A61P 35/00 - Antineoplastic agents

Abstract

Aptamers that bind to and inhibit CTLA-4 and uses thereof in enhancing immune activities, and treating cancer and HIV infection are provided.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

Aptamers that bind to and antagonize PD-1 and uses thereof in promoting T cell proliferation, treating cancer or infectious diseases such as HIV infection.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to a new synthetic route to 4-oxy-2-cyclohexenone and 6-oxy-2- cyclohexenone compounds useful for treatment of cancers and/or diseases, and the intermediates thereto. Examples of these cyclohexenone compounds include, but not limited to, A. cinnamomea active medicinal substances such as antroquinonol, antroquinonol B, antroquinonol C, and antroquinonol D. The intermediates include the compounds of formulae (I), (II) and (III), and the cyclohexenone compounds have the structures of formulae (IV), (V), (VI) and (VII).

IPC Classes  ?

• A61K 31/12 - Ketones
• C07C 49/543 - Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings to a six-membered ring

Abstract

The invention utilizes virtual screening strategy to seek for current market drugs as anti-schizophrenia therapy—drug repurposing. Drug repurposing strategy finds new uses other than the original medical indications of existing drugs. Finding new indications for such drugs will benefit patients who are in needs for a potential new therapy sooner since known drugs are usually with acceptable safety and pharmacokinetic profiles. In this study, repurposing marketed drugs for DAAO inhibitor as new schizophrenia therapy was performed with virtual screening on marketed drugs and its metabolites. The identified and available drugs and compounds were further confirmed with in vitro DAAO enzymatic inhibitory assay.

IPC Classes  ?

• C40B 30/02 - In silico screening
• C40B 30/08 - Methods of screening libraries by measuring catalytic activity
• C40B 30/10 - Methods of screening libraries by measuring physical properties, e.g. mass

Abstract

The present invention provides an implant for pelvic organ prolapse support, comprising an implant for anterior vaginal wall prolapse support which comprises first body having a first angle and a second angle, a pair of first arms and a pair of second arms. The implant for pelvic organ prolapse support of the present invention can treat cystocele and stress urinary incontinence simultaneously, and can optionally combine with an implant for posterior vaginal wall prolapse support and an auxiliary supporter to treat cystocele, stress urinary incontinence, enterocele, uterine prolapse, rectocele prolapse, anal prolapse, and vaginal vault prolapse at one time.

IPC Classes  ?

• A61F 6/08 - Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception

Abstract

A magnetic tunnel junction is provided. The magnetic tunnel junction can enhance the tunnel magnetoresistance ratio and a device including the magnetic tunnel junction. The magnetic tunnel junction includes: a pinned layer; a free layer; and a superlattice barrier, the barrier configured between the pinned layer and the free layer. The magnetic tunnel junction may be a series or parallel connection of the above-mentioned basic form. The device including a magnetic tunnel junction may be a magnetic random access memory bit cell, a magnetic tunnel junction transistor device, a magnetic field sensor, etc.

IPC Classes  ?

• G11C 11/00 - Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor

Abstract

The present invention found that host miRNAs might be involved in Picornavirus pathogenesis through suppression of type I IFNs induction and could act as candidates for developing antiviral therapy. Thus, the invention suggests enterovirus-induced miR-146a facilitates viral pathogenesis by suppressing IFN production and provide a clue to develop the preventive and therapeutic strategies for enterovirus infections.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

A chimera nucleic acid can be obtained from circulatory system for monitoring tumor status. The nucleic acid comprises partial sequence derived from host genome and partial sequence derived from non-host genome. The partial sequence derived from host genome and the partial sequence derived from non-host genome form a chimera junction. The chimera junction is obtained from cell-free nucleic acids and is indicative of disease status.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage

Abstract

Methods, systems, and devices are disclosed for detecting molecular interactions. In one aspect, a device includes a substrate formed of an electrically insulative material, the substrate structured to form (i) a molecular deposition chamber to receive one or more fluid samples including biomolecules, in which the biomolecules are capable of undergoing molecular interactions in the molecular deposition chamber that changes a molecular property of the molecular-interacted biomolecules, and (ii) a microfluidic channel to carry the biomolecules, which, based at least partly on the molecular interactions, the biomolecules travel through the microfluidic channel with different diffusivities; and an electronic sensor including an electrode configured along or at one end of the microfluidic channel and a transistor to detect the changed molecular property of the molecular- interacted biomolecules as a change in electrical signal, in which the electronic sensor is operable to produce an output signal corresponding to the detected electrical signal.

IPC Classes  ?

• G01N 17/00 - Investigating resistance of materials to the weather, to corrosion or to light
• C12M 1/00 - Apparatus for enzymology or microbiology
• G01R 19/00 - Arrangements for measuring currents or voltages or for indicating presence or sign thereof
• H01L 41/00 - SEMICONDUCTOR DEVICES; ELECTRIC SOLID STATE DEVICES NOT OTHERWISE PROVIDED FOR - Details thereof
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

This invention relates to molecular catalysts and chemical reactions utilizing the same, and particularly to molecular catalysts for efficient catalytic oxidation of hydrocarbons, such as hydrocarbons from natural gas. The molecular catalytic platform provided herein is capable of the facile oxidation of hydrocarbons, for example, under ambient conditions such as near room temperature and atmospheric pressure.

IPC Classes  ?

• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst

Abstract

The invention provides DNAzymes which are capable to silence the expression of EGFR at allele-specific level. These allele-specific DNAzymes against EGFR T790M mutation will knockdown the expression of EGFR T790M mRNA while keeping EGFR wild-type mRNA intact. Hence, these allele-specific DNAzymes against EGFR T790M mutation may overcome T790M-derived TKI resistance accompanied with lower unwanted side effects on normal cells in lung cancer patients.

IPC Classes  ?

• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

A microscope apparatus is disclosed. The microscope apparatus comprises a microscope module and an image capture device. The microscope module comprises a housing, a lens element, a sampling assembly, and a light guide element. The lens element is mounted on the housing. The sampling assembly is accommodated in the housing. The light guide element is mounted in the sampling assembly. The sampling assembly is configured to sample a specimen and comprises a cover body and a base body received in the cover body. The cover body has a first top plate and a first anchoring structure connected to the top plate. The base body has a second opt plate and a second anchoring structure connected to the second top plate. The second top plate faces the first top plate to define a holding space for the specimen.

IPC Classes  ?

• G01N 1/02 - Devices for withdrawing samples
• G02B 21/26 - Stages; Adjusting means therefor
• G02B 21/34 - Microscope slides, e.g. mounting specimens on microscope slides

Abstract

The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, and a disease associated with oxidative stress), or inhibiting drug resistance of cancer cells.

IPC Classes  ?

• C07C 235/26 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The invention is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the invention uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.

IPC Classes  ?

• A61K 31/16 - Amides, e.g. hydroxamic acids
• C07C 259/04 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids

Abstract

The present invention provides new compounds of formula I, II or III, which have Src homology-2 containing protein tyrosine phosphatase- 1 (SHP-1) agonist activity. Also provided are treatment methods using the compounds of formula I, II or III.

IPC Classes  ?

• A01N 31/14 - Ethers
• A01N 33/18 - Nitro compounds
• A61K 31/075 - Ethers or acetals

Abstract

The invention provides a method for predicting the response of an EGFR-activating mutant subject suffering from a lung adenocarcinoma and receiving treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and a method for predicting prognosis in an EGFR-activating mutant subject suffering from a lung adenocarcinoma and receiving treatment with EGFR-TKI. In the methods of the invention, clustered genomic alterations in specific chromosomes (in particular chromosomes 5p, 7p, 8q or 14q) are determined as a tool for predicting the response or prognosis.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Abstract

The present invention provides a peptide compound comprising an amino acid sequence of formula X1-X2-Trp-X3-X4-X5 or a pharmaceutically acceptable salt thereof. The present invention also provides a pharmaceutical composition comprising the peptide compound. The present invention also provides a method for inhibiting platelet aggregation, comprising administering an effective amount of the peptide compound or the pharmaceutical composition to a subject in need of such treatment.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• C07K 14/46 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 38/12 - Cyclic peptides
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 7/02 - Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of a-galactosyl ceramides, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are provided, wherein the compounds are immunogenic compounds which serve as ligands for NKT (natural killer T) cells. A process for preparing a chiral compound comprising an R-form or S- form of a glycosphingolipid of formula (1 ) is provided, wherein R1=OH, NH2, NHCOR2, R2 = H or an alkyl, alkenyl, or alkyl terminating in aryl, substituted aryl, heteroaryl, or substituted heteroaryl, X=alkyl group, R3= OH or H, R4=OH or H, R5= aryl, substituted aryl, heteroaryl, or substituted heteroaryl, or a pharmaceutically acceptable salt thereof, wherein the compound of formula 1 is prepared by (a) deprotecting a compound of formula (2): wherein PG is a hydroxyl protecting group, with hydrogen under hydrogenation catalysis.

IPC Classes  ?

• C07H 15/06 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical being a hydroxyalkyl group esterified by a fatty acid
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
• C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
• A61P 31/04 - Antibacterial agents
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to utilisation of a graphene oxide thin film as a hole transport layer in electronic or octoelectronic devices. Provided herein is a device comprising an anode, a hole transport layer comprising a graphene oxide film, an active layer and a cathode.

IPC Classes  ?

• H01L 51/44 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation - Details of devices
• H01L 51/42 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation

Abstract

Described herein are indolyl or indolinyl hydroxamates and pharmaceutical compositions comprising the same, which show histone diacetylase (HDAC) inhibition activity. Also disc a method for treating cancer with these compounds.

IPC Classes  ?

• C07D 209/20 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
• C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 209/22 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
• C07D 209/12 - Radicals substituted by oxygen atoms
• A61K 31/404 - Indoles, e.g. pindolol
• A61P 35/00 - Antineoplastic agents

Abstract

The invention generally relates to compositions and methods of treatment and/or prevention of angiogenesis-related eye diseases using low doses of rhodostomin variants, and in particular, low doses of a fusion protein comprising a rhodostomm variant, wherein the rhodostomin variant is conjugated with a variant of Human Serum Albumin (HSA) where the cysteine residue at position 34 of the HSA amino acid sequence has been replaced with serine.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Abstract

Use of a compound that is a serotonin transporter inhibitor, a selective norepinephrine reuptake inhibitor, or a 5-HT1A agonist for alleviating negative symptoms in a schizophrenia patient who carries a defective neuregulin 1 gene.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• A61P 25/18 - Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The invention generally relates to fusion proteins comprising a rhodostomin variant having an RGD motif variant 48ARLDDL53, wherein the rhodostomin variant is conjugated with a variant of Human Serum Albumin (HSA). The invention also relates to the use of these fusion proteins for treatment and prevention of αvβ3 integrin-associated diseases.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides

Abstract

This invention relates to the use of pterosin compounds of formula I for treating diabetes including type I and type II. Also disclosed is the use of the pterosin compounds for treating obesity.

IPC Classes  ?

• A61K 31/12 - Ketones

Abstract

Disclosed herein is a method of acoustically delivering a therapeutic composition to a subject pre-diagnosed with a tumor. The method comprises the steps of: parenterally administering the composition from a site remote from a tumor location; and exposing the parenterally administering site to ultrasound waves to target the delivery of the composition. The therapeutic composition comprises an effective amount of a polypeptide or a plasmid nucleic acid encoding the polypeptide, the polypeptide or the nucleic acid is suspended in a dispersed medium; and an effective amount of an microbubble contrast agent; wherein the polypeptide is an angiogenesis inhibitor, and the therapeutic composition is capable of reducing the size of the tumor without the risk of inducing viral vector-induced immunogenicity in the subject.

IPC Classes  ?

• A61B 17/20 - Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination

Abstract

This invention provides a method for predicting the post-treatment survival prospect of a cancer patient based on the expression level(s) of microRNAs hsa-miR137, hsa-miR372, hsa-miR182*, hsa-miR221, and hsa-let-7a in that cancer patient.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Abstract

The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung cancer and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens from lung cancer patients. In SCID mice bearing NSCLC xenografts, the targeting phage was able to target tumor masses specifically. When the peptide was coupled to liposomes containing the anti-cancer drugs vinorelbine or doxorubicin, the efficacy of these drugs against human lung cancer xenografts was improved, the survival rate increased, and the drug toxicity was reduced.

IPC Classes  ?

• A61K 9/127 - Liposomes
• C07K 7/04 - Linear peptides containing only normal peptide links
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• C12N 15/09 - Recombinant DNA-technology

Abstract

The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target neovasculature and were identified by in vivo phage display. One such peptide, SP5-52, recognized the neovasculature of multiple tumors in SCED mice, but did not target normal blood vessels. This peptide also binds to blood vessels of human lung cancer biopsy specimens. Liposomes comprising SP5-52 and doxorubicin enhanced the efficacy of the drug against multiple human cancer xenografts in SCED mice.

IPC Classes  ?

• A61K 9/127 - Liposomes
• C07K 7/04 - Linear peptides containing only normal peptide links
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• C12N 15/09 - Recombinant DNA-technology

Abstract

Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin avß3 receptor-antagonist activity and substantially reduced integrin aIIbß3 and/or a5ß1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin aIIbß3 and/or a5ß1 as compared to a wild-type disintegrin. The variant is useful for treatment and/or prevention of avß3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis. The angiogenesis-related eye diseases include age-related macular degeneration, diabetic retinopathy, corneal neovascularizing diseases, ischaemia-induced neovascularizing retinopathy, high myopia, and retinopathy of prematurity.

IPC Classes  ?

• A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imides; Thio-analogues thereof
• A61K 38/00 - Medicinal preparations containing peptides
• C07K 1/00 - General processes for the preparation of peptides
• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• C07K 17/00 - Carrier-bound or immobilised peptides; Preparation thereof
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
• C12N 1/20 - Bacteria; Culture media therefor
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora